#Europe

A Dutch study that offered men Truvada as prevention under either dosing protocol helps shed light on that question.

An analysis of the “on-demand” PrEP study found no new HIV infections among those reporting good adherence and relatively infrequent sex.

In a British study, men on PrEP also reported many psychosocial benefits to using Truvada for prevention.

For the first time, more than half of people with HIV are taking meds. The analysis also shows troubling trends in the former Soviet region.

The science behind Truvada as pre-exposure prophylaxis reveals an awesome tool that is apparently already helping shrink U.S. HIV rates.

Men who have sex with men traveling to the region are advised to get vaccinated for hepatitis A virus.

The HIV population in Western and Southern Europe is nearing the United Nations’ “90-90-90” goals for tackling the epidemic.

Russia has the third-highest number of new HIV infections globally, after South Africa and Nigeria.

Robin Campillo’s “vital new gay classic” follows the Paris chapter of ACT UP in the early 1990s.

Compared with those starting HIV meds in the late 1990s, those who go on treatment today can likely expect to live 10 years longer.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

A study also found that nurse-led counseling sessions influenced quality of life—and length of life.

The risk appears higher among those more recently infected with HIV and those with a higher HIV viral load.

The risk is particularly high the first year after receiving an HIV diagnosis.

The five local clinics that saw the rate drop have gotten more gay and bi men on HIV treatment and seen more accessing PrEP.

Female sex workers in European nations where sex work is not outright forbidden have a lower HIV rate.